The use of recombinant factor VIIa in the treatment of bleeding disorders

Blood

Volumn 104, Issue 13, 2004, Pages 3858-3864

  Roberts, Harold R ^a,b   Monroe, Dougald M ^a   White, Gilbert C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBROTIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BERNARD SOULIER DISEASE; BLEEDING DISORDER; BLEEDING TIME; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BRAIN HEMORRHAGE; DOG; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; GLANZMANN DISEASE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; KIDNEY FAILURE; LIVER DISEASE; NONHUMAN; OCULAR ALBINISM; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN LOCALIZATION; REVIEW; THROMBIN TIME; THROMBOCYTOPATHY; VON WILLEBRAND DISEASE;

EID: 10244270631     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-06-2223     Document Type: Review

References (83)

1. Penner J. Prothrombin complex concentrates and coagulation. Ann Intern Med. 1976;85:531-532.
2. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med. 1980;303:421-425.
3. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: a double-blind clinical trial. N Engl J Med. 1981;305:717-721.
4. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983;62:1135-1138.
5. Hedner U, Nilsson IM, Bergentz SE. Studies on the thrombogenic activities in two prothrombin complex concentrates. Thromb Haemost. 1979; 42:1022-1032.
6. Kingdon HS, Hassell TM. Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions. Blood. 1981;58:868-872.
7. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest. 1983;71:1836-1841.
8. Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis. 1989;19:335-343.
9. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A. 1989;86:1382-1386.
10. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638-648.
11. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost. 2000;26:385-391.
12. Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost. 2000;26:373-377.
13. Roberts H. Is factor VIIa a general hemostatic agent? Yes. J Thromb Haemost. 2004;2:1691-1694.
14. Monroe DM, Roberts HR. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol. 2003;23:8-9; discussion 10.
15. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost. 2003;1:1138-1139.
16. Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology. 2002;35:616-621.
17. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. 2002;99:923-930.
18. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia. 1998;4:331-334.
19. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38:6-9.
20. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1): S61-S65.
21. Hoffman M, Monroe DM, Roberts HR. Cellular interactions in hemostasis. Haemostasis. 1996; 26(suppl 1):12-16.
22. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood. 2004;103:1720-1727.
23. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95:1330-1335.
24. van't Veer C, Mann KG. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemost. 2000;26:367-372.
25. Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler Thromb Vasc Biol. 2003;23:123-129.
26. Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost. 2003;1:1158-1160.
27. Thabut D, de Franchis, Bendtsen F, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A [abstract]. J Hepatol. 2003;38:13.
28. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia. 1998;4:790-798.
29. Shapiro A, Gilchrist GS, Hoots WK, Gastineau DA. Prospective randomized trial of two doses of rFVIIa (Novoseven) in hemophilic patients with inhibitors undergoing surgery. J Thromb Haemost. 1998;80:773-778.
30. Hedner U. Dosing with recombinant factor viia based on current evidence. Semin Hematol. 2004;41:35-39.
31. Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol. 2001;38:43-47.
32. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia. 2001;7:517-522.
33. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost. 2003;1:450-455.
34. Schulman S, d'Oiron R, Martinowitz U, et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S97-S101.
35. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899-909.
36. He S, Blomback M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost. 2003;1:1215-1219.
37. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood. 2003;101:3008-3013.
38. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost. 2002;88:60-65.
39. Roberts HR, Monroe DM III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41:101-108.
40. Lusher J. Acute hemarthroses: the benefits of early versus late treatment with rfVIIa. Blood Coagul Fibrinolysis. 2000;11:S45-S49.
41. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912-918.
42. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding In various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425-432.
43. Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol. 2001;8:312-318.
44. Mariani G, Testa MG, Di Paolantonio T, Molskov Bech, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77:131-136.
45. Bauer KA. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis. 1996; 26(suppl 1):155-158.
46. Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003;101:4783-4788.
47. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26(suppl 1):150-154.
48. Meijer K, Peters FT, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinolysis. 2001;12:211-213.
49. Poon MC, D'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2:1096-1103.
50. Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121:477-481.
51. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nose-bleeds with recombinant factor VIIa. Thromb Haemost. 1998;80:352.
52. del Pozo Pozo AI, Jimenez-Yuste V, Villar A, Quintana M, Hernandez-Navarro F. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis. 2002;13:551-553.
53. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000;83:634-635.
54. Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol. 2004;41:25-29.
55. Thabut D FR, Bendtsen F. Efficacy of recombinant fVIIa in cirrhotic patients with upper gastrointestinal bleeding: a randomized placebo controlled multicenter trial [abstract]. Proc Dig Dis Week. 2003. Abstract 102422.
56. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol. 2001;36:1081-1085.
57. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology. 2004;39:592-598.
58. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930-1937,
59. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71:402-405.
60. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit. 2002;8:CS98-CS100.
61. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke. 2003;34:224-229.
62. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884-888.
63. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol. 2004; 124:653-658.
64. Chan S, Kong M, Minning DM, Hedner U, Marder VJ. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost. 2003;1:760-765.
65. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res. 1989;56:603-609.
66. Catlett JP, Alving BM. Update in hematology. Ann Intern Med. 2002;136:136-143.
67. Friederich PW, Levi M, Bauer KA, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation. 2001;103:2555-2559.
68. Moisescu E, Ardelean L, Simion I, Muresan A, Ciupan R. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis. 2000;11:575-577.
69. Boggio L, Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol. 2001;112: 1074-1075.
70. Henke D, Falk RJ, Gabriel DA. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med. 2004;140:493-494.
71. Bianchi A, Jackson D, Maitz P, Thanakrishnan G. Treatment of bleeding with recombinant factor VIIa in a patient with extensive burns. Thromb Haemost. 2004;91:203-204.
72. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879.
73. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-438; discussion 438-439.
74. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth. 2002;49:S15-S20.
75. Dutton RP HJ, Scalea TM. Recombinant factor VIIa for the control of hemorrhage: early experience in critically ill trauma patients. Can J Anaesth. 2003;5:184-188.
76. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb. 2002; 32(suppl 1):41-46.
77. Meng ZH, Wolberg AS, Monroe DM III, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55:886-891.
78. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med. 2003;4:49-51.
79. Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology. 2003;98:1513-1515.
80. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg. 2002; 94:1369-1370; author reply 370-1361.
81. Waner M. Novel hemostatic alternatives in reconstructive surgery. Semin Hematol. 2004;41:163-167.
82. Friederich P, Heny C, Messelink E, et al. Effects of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double blind placebo controlled trial. Lancet. 2003;361:201-205.
83. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol. 2004;41:20-24.